Advanced Therapy Medicinal Products CDMO Market - Global Forecast 2025-2032

The advanced therapy medicinal products CDMO market is evolving rapidly, presenting contract development and manufacturing organizations with both significant opportunities and complex challenges. Senior executives seeking market clarity must understand the intersection of emerging technologies, shifting regulatory frameworks, and global supply chain pressures shaping future strategies in this sector.

Market Snapshot: Advanced Therapy Medicinal Products CDMO Market

The Advanced Therapy Medicinal Products CDMO Market grew from USD 7.71 billion in 2024 to USD 8.97 billion in 2025. It is expected to continue growing at a CAGR of 17.71%, reaching USD 28.46 billion by 2032.

Scope & Segmentation

This report provides comprehensive insights into the advanced therapy CDMO market, including a review of its major segments, relevant technologies, and key players. It also addresses geographical nuances and service diversity that influence strategic market entry and expansion decisions.

• Product Type: Cell Therapy Products (Non-stem Cell Therapy, Stem Cell Therapy), Gene Therapy Products (Germline Therapy, Somatic Gene Therapy), Tissue Engineered Products
• Service Type: Analytical Testing & Quality Control, Manufacturing Services, Process Development Services, Regulatory & Compliance Support
• Therapeutic Area: Cardiology, Dermatology, Hematology, Neurology, Oncology
• Application: Clinical Stage, Commercial Stage
• End-User: Academic & Research Institutes, Biopharmaceutical Companies
• Region: Americas (United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan)
• Technology: Single-use bioreactors, continuous manufacturing platforms, real-time analytics, modular cleanroom and closed-system processing

• Key Companies: Abzena, Advanced Therapies, LLC, AGC Inc., Aldevron, Almac Group, Bio Elpida by Polyplus, BlueReg, Catalent Inc., CELONIC Group, CGT Catapult, Charles River Laboratories International, Coriolis Pharma Research GmbH, Curia Global, Eurofins Scientific SE, FUJIFILM Diosynth Biotechnologies, Lonza Group, Minaris Regenerative Medicine, Oxford Biomedica PLC, Patheon by Thermo Fisher Scientific Inc., Recipharm AB, Rentschler Biopharma SE, REPROCELL Inc., RoslinCT, Samsung Biologics, VIVEBIOTECH S.L.

Key Takeaways for Senior Decision-Makers

• Scientific advancements and enhanced regulatory pathways are driving rapid adoption of advanced manufacturing and analytics platforms by CDMOs, strengthening compliance and production flexibility in the advanced therapy medicinal products CDMO market.
• Strategic alliances and consortium models assist service providers in balancing risk, leveraging shared expertise, and expediting technology transfer across geographies and project types.
• Segment-specific manufacturing and regulatory requirements for cell, gene, and tissue-based therapies are leading to tailored CDMO service portfolios and specialized operational capabilities.
• Diversifying raw material sourcing combined with supply chain digitalization is mitigating exposure to policy shifts and procurement volatility in key global markets.
• Talent development, with an emphasis on regulatory sciences, quality assurance, and process engineering, is critical as organizations scale capacity and broaden their service scope.

Impact of U.S. Tariff Adjustments on Global Supply Chains

The 2025 introduction of U.S. tariff measures has heightened cost pressures for CDMOs operating within or sourcing components from the United States. These changes have pushed organizations to localize production, expand regional capacity, and enhance risk management through robust supply chain analytics and diversified vendor networks across multiple geographies.

Methodology & Data Sources

This analysis synthesizes primary research via executive interviews with CDMO leaders, biopharma developers, regulators, and suppliers. Supplementary secondary research includes industry publications, regulatory documents, and benchmarking studies. Quantitative analysis leverages capacity and cost modeling, while data triangulation validates trends and outcomes for robust decision-making.

Why This Report Matters

• Gain actionable insights on evolving manufacturing platforms, regulatory dynamics, and resilient supply chain strategies supporting advanced therapies.
• Understand nuanced market segmentation to optimize portfolio alignment, partnership models, and capacity planning initiatives across regions and service areas.

Conclusion

Senior leaders will find this report an essential resource for navigating the evolving advanced therapy medicinal products CDMO market, making informed investments, and developing strategic partnerships that align with both technological advances and shifting global market requirements.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.